Meeting
2023 ASCO Annual Meeting
Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator’s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy.
Authors
Kristine Peregrino Lacuna
Columbia University Irving Medical Center, New York, NY
Kristine Peregrino Lacuna , Sumithra J. Mandrekar , Jacob B. Allred , Stephanie A. Berg , Martee Leigh Hensley , Brian Andrew Van Tine , Suzanne George , Gary K. Schwartz , Matthew Ingham
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT05633381
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS11584)
DOI
10.1200/JCO.2023.41.16_suppl.TPS11584
Abstract #
TPS11584
Poster Bd #
515b
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.
First Author: Matthew Ingham
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo
Poster
2023 ASCO Annual Meeting
A four-tier classification system for studying homologous recombination repair gene reversion mutations as a mechanism of resistance to PARP inhibitors and platinum chemotherapy.
First Author: Qiuxiang Ou
Poster
2023 ASCO Annual Meeting
A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects.
First Author: Elias Chandran